Information Provided By:
Fly News Breaks for September 20, 2017
ARRY
Sep 20, 2017 | 09:09 EDT
Piper Jaffray analyst Edward Tenthoff raised his price target for Array BioPharma to $18 and reiterates an Overweight rating on the shares. The company recently strengthened its balance sheet ahead of next summer's approvals, Tenthoff tells investors in a research note. The FDA accepted new drug applications for binimetinib and encorafenib for BRAF-mutant melanoma and the analyst anticipates approval by the June 30 action date.
News For ARRY From the Last 2 Days
There are no results for your query ARRY
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.